INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.23
+0.12 (+0.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.11
Open14.09
Bid0.00 x 1300
Ask15.32 x 1400
Day's Range13.95 - 14.23
52 Week Range13.07 - 20.54
Volume360,977
Avg. Volume940,856
Market Cap1.441B
Beta (3Y Monthly)0.54
PE Ratio (TTM)3.98
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-09-08
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire2 months ago

    Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

    GlaxoSmithKline plc and Innoviva, Inc. today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta compared to Relvar/Breo Ellipta , in the treatment of patients living with uncontrolled asthma.

  • Business Wire2 months ago

    Innoviva Reports First Quarter 2019 Financial Results

    BRISBANE, Calif.-- -- Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. today reported financial results for the first quarter ended March 31, 2019. Gross royalty revenues of $58.6 million ...

  • Business Wire4 months ago

    Innoviva Reports Fourth Quarter 2018 Financial Results

    BRISBANE, Calif.-- -- Total net revenue rose 15% to $79.9 million in the fourth quarter of 2018 compared with the fourth quarter of 2017. 1 Income before income taxes increased 25% from the fourth quarter of 2017 to $73.1 million. Innoviva, Inc. today reported financial results for the fourth quarter ended December 31, 2018. Gross royalty revenues of $83.3 million from Glaxo Group Limited for the fourth ...

  • GlobeNewswire4 months ago

    Report: Developing Opportunities within Xcel Energy, Empire State Realty Trust, Innoviva, Tyler Technologies, Tower International, and Nathan's Famous — Future Expectations, Projections Moving into 2019

    NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire7 months ago

    Once-daily Trelegy Ellipta gains expanded COPD indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.

  • GlobeNewswire7 months ago

    Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire8 months ago

    Innoviva Reports Third Quarter 2018 Financial Results

    BRISBANE, Calif.-- -- Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third quarter of 2017 to $47.1 million, or $0.43 per diluted share. The Company made a partial repayment of $110.0 million on its Term B loan. Innoviva, Inc. today reported financial results for the third quarter ended ...

  • Business Wire9 months ago

    Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. It would also reference the effect on exacerbations based on data from the InforMing the PAthway of COPD Treatment (IMPACT) study. Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said, “Many patients with COPD continue to experience exacerbations despite taking dual bronchodilator therapies.

  • Business Wire11 months ago

    Innoviva Reports Second Quarter 2018 Financial Results

    BRISBANE, Calif.-- -- Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million, or $0.49 per diluted share. The Company intends to prepay $110 million of its Term B Loan. Innoviva, Inc. today reported financial results for the second quarter ended June 30, ...

  • ACCESSWIRE11 months ago

    Free Technical Research on Insmed and Three More Biotech Equities

    On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).